⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

November 30, 2020Expert Review of Pharmacoeconomics & Outcomes Research

Moving beyond the stage: how characteristics at diagnosis dictate treatment and treatment-related quality of life year losses for women with early stage invasive breast cancer

Karinna Saxby Carolyn Nickson G. Bruce Mann Allan Park Hannah L. Bromley Louiza S. Velentzis P. Procopio Karen Canfell Dennis Petrie

View at Publisher

Ask AI

Bookmark

Share

Abstract

:The associations between ESIBC characteristics and treatment-related QALY losses should be considered when evaluating breast cancer screening and treatment strategies.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Saxby et al. (2020) studied this question.

synapsesocial.com/papers/6a2145655c0c8498e257d509 https://doi.org/10.1080/14737167.2021.1857735

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries2018 · 83,958 citations
2Molecular characteristics of screen-detected vs symptomatic breast cancers and their impact on survivalPrognostic Study · 2009 · 96 citations
3Determinants of Quality of Life for Breast Cancer Patients in Shanghai, ChinaOriginal Research · 2016 · 137 citations
4The impact of a breast cancer screening programme on quality‐adjusted life‐yearsCohort Study · 1991 · 136 citations
5Prognosis in women with interval breast cancer: population based observational cohort studyPrognostic Study · 2012 · 46 citations

Biologic Characteristics of Interval and Screen-Detected Breast Cancers2000
Prognosis of screen-detected breast cancers: results of a population based study2006
Breast cancer recurrence following active treatment: determining its incidence in the NSW population2016
Expert review of pharmacoeconomics and outcomes Research: high impact articles from 2025Expert Review of Pharmacoeconomics & Outcomes Research · 2026
Cost-utility of expanded hypertension screening and treatment among adults covered by Peru’s Seguro integral de salud: a markov Model using national dataExpert Review of Pharmacoeconomics & Outcomes Research · 2026

More from Expert Review of Pharmacoeconomics & Outcomes Research

More from The University of Melbourne

More from The University of Sydney

More from Monash University

More from University of Birmingham

More from Royal Women's Hospital

More from Cancer Council NSW